Spanish Red Biotech Pipeline

MSD

Pembrolizumab/Lenvatinib

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma
Phase: 3Phase III in Spain, 2Phase II, 1Phase I